Procyanidolic Oligomers

Published on 23/06/2015 by admin

Filed under Complementary Medicine

Last modified 23/06/2015

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 2.6 (24 votes)

This article have been viewed 5347 times

Chapter 117 Procyanidolic Oligomers

image General Description

The proanthocyanidins (also referred to as “procyanidins”) are one of the most beneficial groups of plant flavonoids. The most active proanthocyanidins are those bound to other proanthocyanidins. Collectively, mixtures of proanthocyanidin dimers, trimers, tetramers, and larger molecules are referred to as procyanidolic oligomers (PCOs) or oligomeric proanthocyanidins (OPCs).1,2 Although PCOs exist in many plants as well as red wine, commercially available sources of PCOs include extracts from grape seed skin (Vitex vinifera) and the bark of the maritime (Landes) pine.1,2 This chapter reviews the benefits of PCOs from grape seeds and pine bark interchangeably due to their similar chemical composition and pharmacologic profiles.

image History and Folk Use

In 1534, French explorer Jacques Cartier led an expedition up the Saint Lawrence River in what would become North America. Trapped by ice, Cartier and his crew were forced to survive on a ration of salted meat and biscuits. Cartier’s crew began to exhibit signs and symptoms of scurvy, the cause of which was unknown at that time. Fortunately for Cartier and the surviving members of his crew, they met a Native American who advised them to make a tea from the bark and needles of pine trees. As a result, Cartier and his men survived.

More than 400 years later, Professor Jacques Masquelier of the University of Bordeaux, France, read the book Cartier wrote detailing his expedition. Intrigued by Cartier’s story, Masquelier and others concluded that pine bark must contain some vitamin C as well as bioflavonoids, which can exert vitamin C–like effects.

Masquelier termed the active components of the pine bark pycnogenols.1,3 This term was used to describe an entire complex of proanthocyanidin complexes found in a variety of plants, including pine bark, grape seeds, lemon tree bark, peanuts, cranberries, and citrus peels. The term pycnogenol has been replaced in the scientific community by the terms proanthocyanidins, OPC, and PCO. In the United States, Pycnogenol is a registered trademark of Horphag Ltd of Guernsey, United Kingdom, and refers to the PCO extracted from the bark of the French maritime pine.

Masquelier patented the method of extracting PCOs from pine bark in France in 1951 and from grape seeds in 1970. The two PCO sources have volleyed back and forth in popularity based largely on which one is receiving research focus and marketing support.

image Pharmacology

Extracts of PCOs demonstrate a wide range of activity as listed in Box 117-1. Pharmacokinetic studies showed that proanthocyanidins and other breakdown products of PCOs from either grape seed extract or maritime pine are detectable in the serum after oral intake.4,5 Pharmacokinetic studies in humans and animals given C14-labelled PCOs also showed efficient oral absorption.6,7

Antioxidant and Free Radical Scavenging Activity

Perhaps the most celebrated effects of PCOs in the United States are their potent antioxidant and free radical scavenging activities. The antioxidant and free radical scavenging effects of PCOs were discovered by Masquelier in 1986.1

One study evaluated the free radical scavenging activity of PCOs and determined their inhibitory effects on xanthine oxidase (a primary generator of oxygen-derived free radicals) and the lysosomal enzyme system (which governs the release of enzymes that can damage the connective tissue framework acting as a protective sheath around capillary walls).8 This research, summarized in Box 117-2, provides a detailed explanation of the vascular protective action of PCOs and a strong rationale for their use in vascular disease.

In experimental models, the antioxidant activity of PCOs is much greater (approximately 50 times) than that of vitamin C and vitamin E. PCOs reduce lipid peroxidation9 and oxidation of low-density lipoprotein (LDL),10 increase basal levels of α-tocopherol in endothelial cells, protect endothelium from oxidative stress induced by reactive nitrogen species,11,12 and protect endothelial cells from activated macrophage-induced glutathione depletion.13 From a cellular perspective, one of the most advantageous features of PCOs’ free radical scavenging activity is that, because of their chemical structure, they are incorporated into cell membranes. This physical characteristic, along with their ability to protect against both water- and fat-soluble free radicals, provides significant cellular protection against damage by free radicals.8

Antiinflammatory Activity

In vitro and in vivo studies showed PCOs significantly inhibit cyclooxygenase (COX-1) and COX-2 enzymes as well as the formation of proinflammatory cytokines, interleukin-1β, and tumor necrosis factor-β, as well as histamine release from mast cells.1922 When 10 volunteers received a single dose of 300 mg Pycnogenol, within 30 minutes serum samples showed statistically significant inhibition of both COX-1 and COX-2 (P <0.002). Blood samples before and after 5 days administration of 200 mg Pycnogenol to five healthy humans showed similar inhibition.

Cardiovascular Protection

In addition to protecting against oxidative damage to LDL and endothelial cells, PCOs increase erythrocyte membrane fluidity; reduce platelet aggregation; enhance endothelial nitric oxide synthase (eNOS) activity to increase nitric oxide levels; and inhibit angiotensin-I–converting enzyme (ACE).2327 PCO extracts were shown to lower blood cholesterol levels and to shrink the size of cholesterol deposits in arteries in animal and human studies.1,28,29

PCOs also significantly lower C-reactive protein (CRP), a major risk factor for cardiovascular disease. In a double-blind study, 29 subjects in the Pycnogenol group and 26 patients in the placebo group had CRP levels higher than 3 mg/L at baseline.21 After 3-month treatment with Pycnogenol, at a dose of 100 mg/day, CRP significantly decreased plasma free radicals to 70.1% of baseline values. Specifically, plasma CRP levels decreased from 3.9 mg/L at baseline to 1.1 mg/L in the Pycnogenol group, whereas the control group had initial values of 3.9 mg/L that decreased to 3.6 mg/L. Fibrinogen levels were found to be lowered to 62.8% of initial values in the Pycnogenol group.